Cullinan Therapeutics, Inc.

NasdaqGS:CGEM Stock Report

Market Cap: US$639.3m

Cullinan Therapeutics Future Growth

Future criteria checks 2/6

Cullinan Therapeutics's earnings are forecast to decline at 3.6% per annum while its annual revenue is expected to grow at 51.2% per year. EPS is expected to grow by 5.9% per annum. Return on equity is forecast to be -42.7% in 3 years.

Key information

-3.6%

Earnings growth rate

5.9%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate51.2%
Future return on equity-42.7%
Analyst coverage

Good

Last updated29 Jan 2025

Recent future growth updates

Recent updates

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Jan 08

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Nov 20
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Aug 30

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23
Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Sep 22

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Sep 14

Cullinan Oncology grants stock options for 125.7K shares

Sep 02

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24
Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08
Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Jun 30

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 05

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Feb 02

Earnings and Revenue Growth Forecasts

NasdaqGS:CGEM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202757-198N/A-2646
12/31/202633-197N/A-17710
12/31/202513-193N/A-1699
12/31/2024N/A-167N/A-1318
9/30/2024N/A-144-127-127N/A
6/30/2024N/A-142-127-127N/A
3/31/2024N/A-132-122-122N/A
12/31/2023N/A-153-134-134N/A
9/30/2023N/A-156-142-141N/A
6/30/2023N/A-142-163-161N/A
3/31/2023N/A65-157-156N/A
12/31/2022N/A111-128-127N/A
9/30/2022N/A105-117-117N/A
6/30/2022N/A113-73-73N/A
3/31/2022N/A-78-64-64N/A
12/31/202119-66-43-43N/A
9/30/202119-61-38-38N/A
6/30/202119-54-36-36N/A
3/31/202119-47-26-26N/A
12/31/2020N/A-52-30-30N/A
9/30/2020N/A-28-25-25N/A
6/30/2020N/A-25-22-22N/A
3/31/2020N/A-21-21-21N/A
12/31/2019N/A-21-21-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CGEM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CGEM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CGEM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CGEM's revenue (51.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: CGEM's revenue (51.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CGEM is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 13:55
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cullinan Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Kaveri PohlmanBTIG
Thomas ShraderBTIG